1. Introduction {#s0005}
===============

In a variable proportion of cognitively intact older subjects, in vivo amyloid imaging has revealed increased cerebral A*β* deposition, sometimes to a degree identical to that seen in patients with clinically probable Alzheimer\'s disease (AD) ([@bb0005; @bb0190; @bb0220; @bb0235; @bb0270; @bb0295; @bb0300]). This finding has attracted a lot of interest as it may be a possible marker for preclinical Alzheimer\'s disease ([@bb0310]). The only risk factor proven to be associated with increased amyloid load in a cognitively intact population is the apolipoprotein E (APOE) *ε*4 allele ([@bb0110; @bb0220; @bb0280; @bb0355; @bb0360]), which is also a strong risk factor for Alzheimer\'s disease ([@bb0075; @bb0275]). Beyond what can be explained by APOE alone, a family history of AD is associated with increased brain amyloid levels in cognitively intact older adults ([@bb0375]). According to a recent study, polymorphisms of complement component (3b/4b) receptor-1 (*CR1*) modulate the effect of APOE *ε*4 on brain amyloid levels ([@bb0330]). These findings suggest a complex interaction between genetic variants and brain amyloid deposition in preclinical AD ([@bb0310]).

A failure of neural plasticity has been put forward as a unifying theme spanning across the multiple pathways that lead to clinical AD ([@bb0010; @bb0015; @bb0175; @bb0180; @bb0325]). Brain derived neurotrophic factor (BDNF), a neurotrophin with high affinity for tyrosine kinase B receptors (TrkB), has been implicated in neural plasticity ([@bb0120; @bb0370]) as well as in memory, both in humans ([@bb0095]) and in animal models ([@bb0165; @bb0250; @bb0255]). In humans, a common single nucleotide polymorphism (SNP) in the 5′ prodomain of the BDNF gene which results in valine to methionine substitution at codon 66 (*val*66*met*), affects memory function ([@bb0040; @bb0080; @bb0085; @bb0130; @bb0170; @bb0195; @bb0365]), hippocampal volume and fMRI responses ([@bb0085; @bb0260]). The *met* allele occurs in approximately 35% of the Caucasian population ([@bb0035]). Given the prominent role of BDNF in neuroplasticity and a failure of neural plasticity as a potential common theme in AD ([@bb0175]), the BDNF-TrkB pathway could theoretically be linked to a host of AD-related processes at the molecular, neuronal or systems level.

The original hypothesis underlying the design of our study was that BDNF polymorphisms might influence the resilience against *β* amyloid related changes ([@bb0235]). We hypothesized that BDNF *val* carriers would be able to compensate for the presence of *β* amyloid in a better way than *met* carriers. Such resilience might be manifest as a difference between genetic strata in how A*β* load affects cognitive scores and also as a difference in compensatory mechanisms at the brain systems level ([@bb0235]). As a first step, we examined whether there were any direct effects of the BDNF codon 66 polymorphism on amyloid retention in cognitively intact older adults, measured by means of ^18^F-flutemetamol positron emission tomography (PET) ([@bb0155; @bb0240; @bb0345; @bb0350]).

2. Subjects and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

The main cohort consisted of 64 community-recruited older adults between 50 and 75 years of age (mean age = 66, S.D. = 5.1, range 53--74) ([Table 1](#t0005){ref-type="table"}). The study exclusion criteria were a Mini Mental State Examination ([@bb0115]) score lower than 27, a Clinical Dementia Rating score ([@bb0215]) higher than 0, significant neurological or psychiatric history, significant brain lesions on structural MRI, and below-normal test scores on conventional neuropsychological assessment ([Table 1](#t0005){ref-type="table"}). Inclusion was stratified per age bin (50--59, 60--64, 65--69, 70--75) for two genetic factors: BDNF (*met* allele present or absent) and APOE (*ε*4 allele present or absent). The cells of this 2 × 2 factorial design were prospectively matched for number of cases, gender, age, education and handedness (Edinburgh Handedness Inventory) ([Table 1](#t0005){ref-type="table"}). BDNF and APOE variants were genotyped by sequencing at the Genetic Service Facility (GSF, [www.vibgeneticservicefacility.be](http://www.vibgeneticservicefacility.be){#ir0015}) of the VIB Department of Molecular Genetics.

The genetic distribution among all subjects who underwent screening, was 10% BDNF *met* positive (+ ve)/APOE *ε*4 + ve, 16% BDNF *met* negative (-- ve)/APOE *ε*4 + ve, 33% BDNF *met* + ve/APOE *ε*4 − ve, and 41% BDNF *met* − ve/APOE *ε*4 − ve. After genetic stratification, the genetic distribution of the final cohort (n = 64) was as follows: 25% were BDNF *met* + ve/APOE *ε*4 + ve, 23% BDNF *met* − ve/APOE *ε*4 + ve, 25% BDNF *met* + ve/APOE *ε*4 − ve, and 27% were BDNF *met* − ve/APOE *ε*4 − ve.

The protocol was approved by the Ethics Committee University Hospitals Leuven (EudraCT: 2009-014475-45) and written informed consent was obtained from all subjects in accordance with the Declaration of Helsinki.

2.2. Image acquisition {#s0020}
----------------------

^18^F-flutemetamol PET imaging was performed at the University Hospitals Leuven. The acquisition procedure has been described before ([@bb0155; @bb0240; @bb0345; @bb0350]). Images were acquired on a 16-slice Siemens Biograph PET/CT scanner (Siemens, Erlangen, Germany). The PET tracer was injected intravenously as a bolus (mean activity 150.6 MBq, S.D. 8 MBq, range 137.9--192.5 MBq) in an antecubital vein. Image acquisition started 90 min after tracer injection and lasted for 30 min. Prior to the PET scan, a low-dose computed tomography (CT) scan was performed for attenuation correction. Random and scatter corrections were also applied. Images were reconstructed using Ordered Subsets Expectation Maximization (OSEM; 4 iterations × 16 subsets).

A high-resolution T1-weighted structural MRI was obtained on a 3 T Philips Intera system equipped with an 8-channel receive-only head coil (Philips SENSitivity Encoding head coil), using a 3D turbo field echo sequence (coronal inversion recovery prepared 3D gradient-echo images, inversion time 900 ms, TR = 9.6 ms, TE = 4.6 ms, flip angle 8°, field of view = 250 × 250 mm, 182 slices; voxel size 0.98 × 0.98 × 1.2 mm^3^).

2.3. Image analysis {#s0025}
-------------------

All analyses were performed using Statistical Parametric Mapping 8 (SPM8, <http://www.fil.ion.ucl.ac.uk/spm>). The PET data were reconstructed as 6 frames of 5 min and realigned to the first frame to correct for potential head motion. Subsequently, the 6 frames were summed to create one summed image. The individual\'s T1-weighted structural image was then co-registered to his/her PET summed image. This MR image was subsequently normalized to the SPM8 T1 template in Montreal Neurological Institute (MNI) space using a unified segmentation approach. Next, this normalization matrix was applied to the individual\'s co-registered PET summed image.

From the spatially normalized images (voxel size 2 × 2 × 2 mm^3^) standardized uptake value ratios (SUVR) were calculated with cerebellar gray matter as reference region, resulting in SUVR images. The cerebellar gray matter reference region was defined as areas 91 to 108 of the Automated Anatomical Labelling atlas (AAL) ([@bb0340]). The cerebellar reference region was resliced to each individual\'s normalized PET summed image. In order to exclude white matter (WM) content, it was masked by the normalized and modulated subject-specific gray matter (GM) map, with the threshold for masking set at 0.3.

We also defined a composite cortical volume of interest. This was composed of 5 bilateral cortical areas, i.e. frontal, parietal, anterior cingulate, precuneus/posterior cingulate and lateral temporal defined as AAL areas 3--10, 13--16, 23--28, 31--32, 35--36, 57--70, 81--82, 85--90. The composite cortical VOI was resliced to each individual\'s normalized PET summed image. In order to exclude WM content, it was masked by the normalized and modulated subject-specific GM map, with the threshold for masking set at 0.3.

In one of the subjects the structural T1 image was missing due to a contraindication for MRI. This individual\'s PET summed image was normalized to the group mean normalized PET summed image created from the 63 remaining subjects. The AAL-derived cerebellar and composite cortical VOIs were co-registered to this normalized PET summed image and were masked with the mean normalized modulated GM map (thresholded at 0.3) created out of the 63 normalized modulated GM maps. This individual\'s SUVR image was calculated based on this normalized PET summed image with the cerebellar gray matter reference region.

As a secondary measure we also worked on partial volume corrected (PVC) data. PVC was based on the MRI using the modified Müller-Gärtner method ([@bb0225]). This method determines tracer concentration per unit volume of GM. In the modified method, we use probabilistic segmentation instead of binary maps. The normalized unmodulated GM and WM segmentations were used to estimate different tissue fractions per voxel. PVC was applied to the normalized PET summed images. The remaining procedures were identical to those outlined above.

We also tested for any group differences in tracer retention in the cerebellar reference region, as this could cause spurious differences in cortical SUVR values. We calculated the standardized uptake values (SUV) in the cerebellar gray matter region. SUV values were defined as the ratio of mean activity concentration in cerebellar gray matter in the normalized PET summed image \[MBq\] to the injected activity concentration \[MBq/kg\] per total body weight \[kg\].

### 2.3.1. Statistical analysis {#s0030}

We statistically analyzed all SUVR images using two approaches: one was based on the global composite cortical VOI, the other was voxel-based. In the global composite cortical analysis our primary outcome measure was mean SUVR value calculated in the composite cortical VOI (SUVR*~comp~*). We used SUVR*~comp~* as the dependent variable and performed a factorial ANOVA with BDNF (2 levels: *met* allele present vs absent) and APOE (2 levels: *ε*4 allele present vs absent) as between-subjects factors. In addition, we performed a confirmatory non-parametric Kruskal--Wallis ANOVA on the 4 genetic groups with SUVR*~comp~* as the dependent variable.

In the voxel based analysis, using SPM8, we analyzed SUVR images by means of a factorial ANOVA with BDNF (2 levels: *met* allele present vs absent) and APOE (2 levels: *ε*4 allele present vs absent) as between-subjects factors. The significance threshold was set at a cluster-level of *P* \< 0.05 family-wise error (FWE) corrected for the entire brain search volume, with the voxel-level threshold set at uncorrected *P* \< 0.001.

The partial-volume corrected data were analyzed using a factorial ANOVA with BDNF (2 levels: *met* allele present vs absent) and APOE (2 levels: *ε*4 allele present vs absent) as between-subjects factors.

Differences in the SUV values in the cerebellar gray matter VOI were analyzed by a factorial ANOVA with 2 between-subjects factors: BDNF (2 levels: *met* allele present vs absent) and APOE (2 levels: *ε*4 allele present vs absent).

2.4. Relationship to episodic memory test scores {#s0035}
------------------------------------------------

To assess the relationship between ^18^F-flutemetamol retention and episodic memory measures, we conducted a linear regression analysis with either AVLT delayed recall score (DR) or total learning score (TL) as dependent variable and SUVR*~comp~* as independent variable. This analysis was performed across the entire group as well as within each genetic group separately. To evaluate whether the relationship was specifically observed with episodic memory scores, we also performed a linear regression analysis with other tests from our cognitive battery: Boston Naming Test (BNT), Animal Verbal Fluency Test (AVF) and total score on Raven\'s Progressive Matrices (RPM).

3. Results {#s0040}
==========

The four genetic groups did not differ in age, gender, years of education or neuropsychological test scores ([Table 1](#t0005){ref-type="table"}).

3.1. Effect of APOE and BDNF polymorphisms on SUVR {#s0045}
--------------------------------------------------

### 3.1.1. Global composite cortical analysis {#s0050}

Our primary outcome measure, SUVR*~comp~*, differed significantly between the four genetic groups (*F*(3,60) = 5.37, *P* = 0.002) ([Fig. 1](#f0005){ref-type="fig"}). The main effect of APOE was significant: APOE *ε*4 carriers had significantly higher ligand retention than APOE *ε*4 noncarriers (*F*(1,60) = 7.14, *P* = 0.01). The main effect of BDNF genotype was not significant (*F*(1,60) = 1.02, *P* = 0.32). The interaction between BDNF and APOE on ligand retention was significant (*F*(1,60) = 7.94, *P* = 0.007): BDNF *met* + ve/APOE *ε*4 + ve carriers had significantly higher ligand retention (mean SUVR*~comp~* = 1.37, S.D. = 0.21) than BDNF *met* − ve/APOE *ε*4 + ve carriers (mean SUVR*~comp~* = 1.23, S.D. = 0.12) (*P* = 0.01), while amyloid ligand retention in APOE *ε*4 noncarriers did not differ between BDNF *met* + ve (mean SUVR*~comp~* = 1.17, S.D. = 0.06) and BDNF *met* − ve cases (mean SUVR*~comp~* = 1.24, S.D. = 0.11) (*P* = 0.2) ([Fig. 2](#f0010){ref-type="fig"}A and B).

Non-parametric analysis confirmed these results. The four genetic groups differed significantly in SUVR*~comp~* (*H*(df 3, N 64) = 11.35, *P* = 0.01). The main effect of APOE was significant: APOE *ε*4 carriers had significantly higher ligand retention than APOE *ε*4 noncarriers (*H*(df 1, N 64) = 5.25, *P* = 0.02). The main effect of BDNF genotype was not significant (*H*(df 1, N 64) = 0.04, *P* = 0.85). Planned comparisons revealed that BDNF *met* + ve/APOE *ε*4 + ve carriers exhibited higher ligand retention (mean rank = 19.1) than BDNF *met* − ve/APOE *ε*4 + ve carriers (mean rank = 12.6) (*P* = 0.048). Amyloid ligand retention tended to be lower in BDNF *met* + ve (mean rank = 13.8) than in BDNF *met* − ve (mean rank = 19.9) APOE *ε*4 noncarriers (*P* = 0.07).

Analysis of partial volume corrected data confirmed these results. PVC SUVR*~comp~* was significantly different between the four genetic groups (*F*(3,59) = 4.64, *P* = 0.006). The main effect of APOE was significant: APOE *ε*4 carriers had significantly higher ligand retention than APOE *ε*4 noncarriers (*F*(1,59) = 6.96, *P* = 0.01). The main effect of BDNF genotype was not significant (*F*(1,59) = 0.55, *P* = 0.46). The interaction between BDNF and APOE on ligand retention was significant (*F*(1,59) = 6.7, *P* = 0.01): BDNF *met* + ve/APOE *ε*4 + ve carriers had significantly higher ligand retention (mean SUVR*~comp~* = 1.56, S.D. = 0.39) than BDNF *met* − ve/APOE *ε*4 + ve carriers (mean SUVR*~comp~* = 1.36, S.D. = 0.24) (*P* = 0.02), while amyloid ligand retention in APOE *ε*4 noncarriers did not differ between BDNF *met* + ve (mean SUVR*~comp~* = 1.24, S.D. = 0.09) and BDNF *met* − ve cases (mean SUVR*~comp~* = 1.35, S.D. = 0.18) (*P* = 0.19).

SUV values in cerebellar gray matter did not differ between genetic groups (*F*(3,60) = 0.54, *P* = 0.66): There was no difference between APOE *ε*4 carriers and noncarriers (*F*(1,60) = 0.21, *P* = 0.65), between BDNF *met* carriers and noncarriers (*F*(1,60) = 0.55, *P* = 0.46) and neither was there any interaction (*F*(1,60) = 0.79, *P* = 0.38).

### 3.1.2. Voxel-based analysis {#s0055}

The whole-brain voxel-wise analysis confirmed the findings from the composite cortical analysis. There was a significant main effect of APOE: APOE *ε*4 carriers had significantly higher ^18^F-flutemetamol retention than APOE *ε*4 noncarriers in the posterior cingulate (cluster peak − 14, − 20, 40, *Z* = 4.26, extent of voxels (ext.) 178 mm^3^, corr. cluster-level *P* = 0.025) ([Fig. 3](#f0015){ref-type="fig"}A). There was no main effect of BDNF genotype (corr. cluster-level P \> 0.7). The interaction effect of APOE and BDNF was significant in precuneus (cluster peak 10, − 40, 42, *Z* = 4.71, ext. 437 mm^3^, corr. cluster-level *P* = 0.0001), left orbitofrontal cortex (cluster peak − 8, 64, − 14, *Z* = 4.69, ext. 387 mm^3^, corr. cluster-level *P* = 0.0003), right orbitofrontal cortex (cluster peak 16, 68, − 2, *Z* = 4.37, ext. 240 mm^3^, corr. cluster-level *P* = 0.006), left gyrus rectus (cluster peak − 8, 22, − 18, *Z* = 4.62, ext. 252 mm^3^, corr. cluster-level *P* = 0.004), right gyrus rectus (cluster peak 16, 28, − 28, *Z* = 4.35, ext. 209 mm^3^, corr. cluster-level *P* = 0.012), right middle frontal gyrus (cluster peak 34, 46, 28, *Z* = 4.14, ext. 316 mm^3^, corr. cluster-level *P* = 0.001) and right inferior frontal sulcus (cluster peak 50, 38, 6, *Z* = 3.88, ext. 281 mm^3^, corr. cluster-level *P* = 0.002) ([Fig. 3](#f0015){ref-type="fig"}B). Simple effects revealed that BDNF *met* + ve/APOE *ε*4 + ve carriers had higher ligand retention than BDNF *met* − ve/APOE *ε*4 + ve carriers in posterior cingulate (cluster peak at 2, − 32, 42, *Z* = 4.25, ext. 388 mm^3^, corr. cluster-level *P* = 0.0003), gyrus rectus (cluster peak at − 4, 34, − 26, *Z* = 4.44, ext. 196 mm^3^, corr. cluster-level *P* = 0.016), insula (cluster peak at 36, 8, − 12, *Z* = 4.89, ext. 311 mm^3^, corr. cluster-level *P* = 0.001) and posterior middle temporal cortex (cluster peak at 62, − 62, 4, *Z* = 4.23, ext. 168 mm^3^, corr. cluster-level *P* = 0.03). There was no difference between BDNF *met* + ve/APOE *ε*4 − ve carriers and BDNF *met* − ve/APOE *ε*4 − ve carriers (corr. cluster-level *P* \> 0.9).

### 3.1.3. Relationship between *β* amyloid load and episodic memory {#s0060}

Across the entire sample, SUVR*~comp~* did not correlate with AVLT DR (*P* = 0.38) or TL (*P* = 0.16). When analyzed per genetic group, a highly significant and negative correlation was seen only in the group of BDNF *met* + ve/APOE *ε*4 + ve carriers (DR: *r* = − 0.62, *P* = 0.01, and TL: *r* = − 0.58, *P* = 0.02) ([Fig. 4](#f0020){ref-type="fig"}A and B, red lines). In the other groups the correlation remained far below significance (*P* \> 0.49) ([Table 2](#t0010){ref-type="table"}). A formal pairwise comparison however of the regression slopes between groups did not reach significance (*P* \> 0.05) ([@bb0335]).

None of the other cognitive test scores showed any correlation with *β* amyloid when tested across the entire sample (*P* \> 0.17) or per group ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0065}
=============

Our study revealed two key novel findings. First, APOE *ε*4 carriers exhibited a higher *β* amyloid load in the presence of one or two BDNF *met* alleles compared to BDNF *met* noncarriers ([Figs. 1, 2](#f0005 f0010){ref-type="fig"}). Second, an inverse relationship between A*β* load and episodic memory exists in BDNF *met*/APOE *ε*4 carriers but not in any of the other subgroups.

The interaction effect between BDNF and APOE on *β* amyloid load was unexpected and needs further confirmation by independent studies. The genetic stratification for APOE and BDNF prior to recruitment for scanning is a unique feature of our cohort that was probably critical for obtaining this novel finding. In the group of individuals volunteering for this study, after applying all non-genetic criteria for in/exclusion, the proportion of BNDF *met* + ve/APOE *ε*4 + ve subjects was only 10%. After stratification this was raised to 25%. It is this genetic combination that drives the interaction. Had we not strived for a balanced factorial design with cells matched for numbers at recruitment, the interaction effect would almost certainly have been missed. This means that we had to genotype much higher numbers of subjects than were actually able to enter the scanning phase of the study. Replication of the interaction effect will probably also have to be based on samples enriched for the naturally least frequent combination of BNDF *met* and APOE *ε*4 carriers.

Most of the subjects with raised amyloid were APOE *ε*4 carriers with BDNF *met* allele at codon 66 ([Fig. 1](#f0005){ref-type="fig"}). The number of subjects with raised amyloid is relatively low but impacts relatively strongly on the statistical outcome. Non-parametric testing confirmed that BDNF *met* carriage affected A*β* load. Our findings were obtained in a cohort stratified at recruitment for APOE and BDNF polymorphisms according to a balanced factorial design with demographically matched subjects. The stratification, the balanced design and the fact that we only tested these two gene polymorphisms, reduces the risk of a false-positive. As a relatively low number of the 64 healthy subjects had a raised A*β* load, the power of our study to determine an influence of genetics is limited and any negative findings should be interpreted with caution. The proportion of subjects with raised amyloid increases with age ([@bb0220]). Further studies in a higher age range will be needed to confirm whether the interaction is present also in an older population.

We used the volumetric MRI scan for normalization and the segmented gray matter maps for definition of the cerebellar gray matter and the composite cortical volume. The method we applied differs from the purely PET-based method applied in the phase 2 study of ^18^F-flutemetamol ([@bb0345]). As a consequence, we cannot simply use the cut-off from the phase 2 study to discriminate positive from negative cases in a binary manner. Furthermore, in a cognitively intact population of older adults, a significant minority exhibits intermediary values. While categorical discrimination between positive and negative individuals is relevant for clinical purposes, a binary division in positive and negative cases is not essential for the current scientific question.

The interaction effect was seen in frontobasal cortex, precuneus, and lateral prefrontal cortex, which are well-established areas of predilection for amyloid deposition in the initial phase of the disease ([@bb0005; @bb0105; @bb0110; @bb0190; @bb0270; @bb0295]). For posterior cingulate and precuneus this has been linked to their status as a network hub ([@bb0025; @bb0210]), including their centrality in the connections from the hippocampal formation to parietal cortex ([@bb0185; @bb0305]). Why orbitofrontal cortex regularly recurs as an area of predilection, is less clear. In any case, numerous studies of the earliest changes in amyloid load in AD have reported increased amyloid load in this region ([@bb0020; @bb0045; @bb0050; @bb0105; @bb0110]). Orbitofrontal cortex also shows hypometabolism on ^18^F-deoxyglucose PET early in the AD disease course ([@bb0135]).

The original purpose of our factorial design was to evaluate the effect of BDNF on functional reorganization and plasticity ([@bb0235]) in response to *β* amyloid related injury. We predicted that compared to BDNF *met* carriers BDNF *val* status would confer a higher compensatory capacity for functional reorganization in the face of increased A*β* amyloid ([@bb0235]). Given ample evidence for a relationship between BDNF polymorphism and episodic memory ([@bb0040; @bb0080; @bb0085; @bb0130; @bb0170; @bb0195; @bb0365]) and given the prominent role of episodic memory decline in the earliest clinical stages of Alzheimer\'s disease, we primarily evaluated whether BDNF affected the relationship between A*β* deposition and episodic memory. We found a strong negative correlation between A*β* deposition and episodic memory encoding and recall in the BDNF *met* + ve/APOE *ε*4 + ve carriers but not in any of the three other groups ([Fig. 4](#f0020){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). This finding is in line with our a priori hypothesis that BDNF polymorphism may influence resilience against A*β* related injury. A formal pairwise comparison however of the regression slopes of *β* amyloid load versus episodic memory scores between the groups did not reach significance, possibly due to the relatively small sample size. The relationship between cognitive test scores in cognitively intact individuals and A*β* deposition is still a topic of active research, with some studies reporting an inverse relationship and others an absence of any relationship ([@bb0050; @bb0205; @bb0270; @bb0285; @bb0290]). Our findings offer one possible explanation for this divergence between studies: if the genetic composition differs between cohorts, this may cause differences in how *β* amyloid load relates to episodic memory scores ([Fig. 4](#f0020){ref-type="fig"} A, B). The effect of A*β* load on episodic memory scores in the BDNF *met* + ve/APOE *ε*4 + ve group highlights the behavioral relevance of our findings.

Previous studies have shown the negative effect of BDNF codon 66 *val* to *met* substitution on a number of parameters: It is associated with worse memory function ([@bb0040; @bb0085; @bb0130; @bb0170; @bb0195; @bb0365]), lower fMRI responses in hippocampi during both encoding and retrieval ([@bb0085; @bb0130]), smaller volumes of hippocampi ([@bb0030; @bb0125; @bb0195; @bb0260; @bb0320]), lateral prefrontal cortex ([@bb0245; @bb0260; @bb0385]), temporal neocortex, cingulate, and insula ([@bb0385]), and amygdalae ([@bb0200; @bb0315]), as well as age-related volume reduction of other cortical areas which may be gender-dependent ([@bb0245]). The BDNF codon 66 *met* allele also affects white matter connectivity ([@bb0055]). Interestingly, a recent study reported effects of BDNF *val*66*met* polymorphism on brain metabolism in healthy controls, MCI and AD cases ([@bb0380]). To the best of our knowledge our study is the first to directly examine how the well-studied negative effects of BDNF *met* relate to subclinical A*β* amyloid and its relationship to episodic memory.

An interaction effect between BDNF and APOE on amyloid ligand retention has not been reported in previous genome-wide association studies (GWAS) of clinically probable Alzheimer\'s disease patients. In their conventional form, GWAS make use of massively univariate single-locus tests. Such tests are designed to search for single disease-associated polymorphisms ([@bb0150]) where each gene variant is tested individually for association with a specific phenotype (cases versus controls) ([@bb0070]). GWAS in their classical form will miss interaction effects between genes.

Apart from amyloid load, it is currently unknown how the interaction between BDNF and APOE polymorphisms affects other contributors to the pathogenesis of AD, such as synapse loss, cholinergic depletion, or neurofibrillary tangle formation. For this reason, it remains to be seen whether the interaction effect between BDNF and APOE on amyloid burden we observed in cognitively intact subjects can be extrapolated to genetic comparisons between clinically probable AD and controls.

Studies in animal models of AD offer us with several putative mechanisms through which BDNF and the amyloid cascade may interact. Intra-hippocampal injections of A*β*(1--42) in rats reduce the expression of BDNF and also result in decreased BDNF levels in prefrontal cortex ([@bb0060]). In amyloid precursor protein (APP) double transgenic mice with both the Swedish and the Indiana APP mutations, BDNF gene delivery to entorhinal cortex reverses synapse loss and improves cell signaling, partially normalizes APP-related alterations in hippocampal and entorhinal gene expression, and restores learning and memory ([@bb0230]). In AD postmortem samples, BDNF protein expression as well as mRNA levels are decreased in hippocampi and other cortical areas ([@bb0065; @bb0100; @bb0140; @bb0145; @bb0265]). During the course of AD, BDNF serum concentration levels correlate with the severity of dementia: levels are increased in early stages of AD and decreased in the advanced stages ([@bb0090; @bb0160]). It however is difficult to speculate on the exact mechanism through which BDNF may interact with APOE to increase amyloid burden as the relationship between APOE and increased amyloid aggregation itself is still relatively poorly understood. Both genes have been implicated in neural plasticity. This concept encompasses widely diverse processes ([@bb0175]). Possibly, the efficacy with which neurons dispose of toxic forms of A*β* may depend on pathways that are linked to lipid metabolism and neuronal survival in which APOE and BDNF, respectively, play pivotal roles.

In conclusion, we demonstrate an association between BDNF *met* allele and PET measures of amyloid deposition in cognitively normal older adult APOE *ε*4 carriers. This finding provides empirical evidence for a role of the BDNF-TrkB pathway not only in neural plasticity but also in the pathogenesis of Alzheimer\'s disease ([@bb0175]). It underscores the opportunity to use brain imaging measurements to help characterize the individual and epistatic effects of putative genetic risk factors in the predisposition to AD. We however would like to emphasize that the current study is hypothesis-generating and needs further replication.
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![Distribution of ^18^F-flutemetamol retention levels for the different genetic groups. X axis: age in years; Y axis: SUVR*~comp~*.](gr1){#f0005}

![Effects of BDNF and APOE genotypes on amyloid deposition measured by SUVR*~comp~*. (A) SUVR*~comp~* in the different genetic subgroups. (B) Further differentiation depending on APOE and BDNF subgroups.](gr2){#f0010}

![Statistical parametric map of the main effect of APOE (A) and the interaction effect between APOE and BDNF (B). (A) Main effect of APOE genotype: increased ^18^F-flutemetamol retention in APOE *ε*4 + ve carriers compared to APOE *ε*4 − ve carriers in the posterior cingulate. (B) Interaction effect between BDNF and APOE: increased ^18^F-flutemetamol retention in the precuneus, orbitofrontal cortex, gyrus rectus, middle frontal gyrus, and inferior frontal sulcus. Images are displayed at voxel-level *P* \< 0.001, only clusters that reached corrected cluster-level *P* \< 0.05 are shown. SPM *t* maps are projected onto axial, sagittal, and coronal sections of the SPM8 standard single subject T1 template and as SPM8 glass brain views.](gr3){#f0015}

![Correlation between amyloid ligand retention and AVLT delayed recall (DR) and total learning (TL) scores. (A) Negative correlation between SUVR*~comp~* values and AVLT DR scores in the BDNF *met* + ve/APOE *ε*4 + ve group (red line). (B) Negative correlation between SUVR*~comp~* values and AVLT TL scores in the BDNF *met* + ve/APOE *ε*4 + ve (red line). SUVR*~comp~* (Y axis) plotted by AVLT DR or TL scores (X axis): BDNF *met* + ve/APOE *ε*4 + ve (red triangles), BDNF *met* − ve/APOE *ε*4 + ve (blue squares), BDNF *met* + ve/APOE *ε*4 − ve (red circles) and BDNF *met* − ve/APOE *ε*4 − ve (blue diamonds). When the correlation does not reach significance, no regression line is shown.](gr4){#f0020}

###### 

Demographic and neuropsychological characteristics of subjects in the original dataset. Values represent means and standard deviations (in parenthesis) unless stated otherwise; gender is expressed in number of individuals. Abbreviations: M = male; F = female; MMSE = Mini Mental State Examination; CDR = Clinical Dementia Rating global score; AVLT = Rey Auditory Verbal Learning Test; DR = delayed recall; TL = total learning; TMT = Trail Making Test part B divided by part A; BNT = Boston Naming Test; AVF = Animal Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM = Raven\'s Progressive Matrices; + ve  =  positive; - ve  =  negative.

  Demographic data and neuropsychological test scores in the original dataset                                                           
  ----------------------------------------------------------------------------- ------------- ------------- ------------- ------------- ------
  Gender (M/F)                                                                  7/9           9/6           8/8           10/7          0.8
  Age                                                                           65.4 (5.5)    66.5 (4.3)    65.3 (5.5)    65.8 (5.4)    0.9
  Education (years)                                                             13.3 (3.0)    12.5 (2.2)    13.9 (2.2)    14.7 (3.6)    0.2
  Handedness                                                                    95.0 (14.5)   100.0 (0.0)   96.7 (7.7)    100.0 (0.0)   0.2
  MMSE (/30)                                                                    29.0 (0.9)    28.7 (1.1)    29.3 (0.6)    28.9 (0.9)    0.3
  AVLT DR (/15)                                                                 11.4 (2.4)    10.3 (3.6)    11.3 (2.8)    10.6 (2.2)    0.6
  AVLT TL (/75)                                                                 48.9 (7.8)    50.1 (8.6)    51.1 (12.3)   49.0 (9.1)    0.9
  BNT (/60)                                                                     53.1 (5.4)    51.9 (6.5)    52.6 (4.8)    54.2 (3.2)    0.6
  AVF                                                                           18.6 (4.7)    19.9 (5.3)    21.8 (5.5)    21.2 (4.2)    0.3
  LVF                                                                           33.5 (11.8)   31.1 (8.1)    33.6 (9.9)    37.4 (9.8)    0.4
  RPM                                                                           39 (8.6)      42.1 (9.2)    44.3 (7.3)    46.5 (7.5)    0.07
  TMT B/A                                                                       2.9 (1.0)     2.5 (0.6)     2.6 (1.0)     2.5 (1.1)     0.5

###### 

Linear regression analysis between SUVR*~comp~* and cognitive test scores in each of the four genetic groups. Values represent correlation coefficient (*r*) and statistical significance (*P*). Abbreviations: AVLT = Rey Auditory Verbal Learning Test; DR = delayed recall; TL = total learning; BNT = Boston Naming Test; AVF = Animal Verbal Fluency Test; RPM = Raven\'s Progressive Matrices.

  Correlation between amyloid tracer retention and cognitive test scores                                                    
  ------------------------------------------------------------------------ ------ ------ ------ ------ ------ ------ ------ ------
  AVLT DR                                                                  0.62   0.01   0.14   0.61   0.19   0.49   0.15   0.56
  AVLT TL                                                                  0.58   0.02   0.18   0.51   0.12   0.65   0.02   0.95
  BNT                                                                      0.18   0.49   0.03   0.91   0.06   0.81   0.07   0.78
  AVF                                                                      0.04   0.88   0.21   0.44   0.11   0.69   0.42   0.09
  RPM                                                                      0.36   0.17   0.00   1.00   0.03   0.92   0.10   0.72
